Abstract:
There is growing clamour of late that the evaluation of new pharmaceuticals should not only contain analysis of safety and efficacy, but also elements of economic analysis. The reason: the quality of present-day background material is such that it does not permit thorough-going assessment of the impact that a new drug has on the economy. A splendid opportunity to subject a new pharmaceutical to an economic evaluation will arise when the pharmaceutical undergoes clinical trial; this will be especially true of phase-3 trials. The main problem posed by many economic analyses is precisely the lack of data that can be used for prospective purposes.
This could also be of interest:
Research Papers
The role of marketing research in identifying the need for cost benefit analysis
Catalogue: EphMRA/ESOMAR Seminar 1991: 1993 And Beyond
Author: David Dawson
 
March 6, 1991
Research Papers
Pharmaceutical industry competitor analysis
Catalogue: EPHMRA/ESOMAR Seminar 1985: Pharmaceutical Competitor Analysis
Author: Christina Heuer
 
February 27, 1985
